Nyxol Demonstrated a Favorable Safety Profile and Rapidly Reversed Dilated Eyes in Pediatric Subjects 3 to 11 Years Old, Consistent with Findings in MIRA-2 and MIRA-3 Phase 3 Registration Trials
MIRA-4 Results Support Potential Broader Label for Nyxol in RM to Include Pediatrics
NDA Filing for Nyxol in RM Planned for Late 2022 with Potential Launch in 2H 2023
https://finance.yahoo.com/news/ocuphire-completes-last-clinical-trial-110000761.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.